Back to News
Market Impact: 0.35

Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates

ESPR
Corporate EarningsHealthcare & BiotechCompany FundamentalsAnalyst Estimates

Esperion reported quarterly EPS of $0.22, missing the Zacks consensus of $0.23 by $0.01; this compares with a loss of $0.10 per share in the year-ago quarter. The result is a minor miss against estimates but a material year-over-year improvement, implying a mixed near-term signal for the stock with limited likely price movement.

Analysis

Esperion reported quarterly EPS of $0.22, missing the Zacks consensus of $0.23 by $0.01; this compares with a loss of $0.10 per share in the year-ago quarter. The result is a minor miss against estimates but a material year-over-year improvement, implying a mixed near-term signal for the stock with limited likely price movement.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Demo

Market Sentiment

Overall Sentiment

mixed

Sentiment Score

0.00

Ticker Sentiment

ESPR-0.15